The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 05, 2020

Filed:

Jan. 23, 2015
Applicant:

Quarrymen & Co. Inc., Tokyo, JP;

Inventor:

Minoru Ueda, Tokyo, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/00 (2006.01); A61K 38/30 (2006.01); C12N 5/074 (2010.01); A61K 35/12 (2015.01); A61K 38/18 (2006.01); A61K 38/19 (2006.01); C12N 5/0775 (2010.01); A61K 35/32 (2015.01);
U.S. Cl.
CPC ...
A61K 38/30 (2013.01); A61K 35/12 (2013.01); A61K 38/1841 (2013.01); A61K 38/1866 (2013.01); A61K 38/195 (2013.01); C12N 5/0664 (2013.01); C12N 5/0696 (2013.01); A61K 35/32 (2013.01); C12N 2500/02 (2013.01); C12N 2500/90 (2013.01); C12N 2500/99 (2013.01); C12N 2501/105 (2013.01); C12N 2501/15 (2013.01); C12N 2501/165 (2013.01); C12N 2501/21 (2013.01); C12N 2501/60 (2013.01); C12N 2501/998 (2013.01); C12N 2506/1361 (2013.01); C12N 2510/04 (2013.01);
Abstract

The invention provides a novel anticancer therapeutic having a high effect against solid cancers, lacking the side effects of chemotherapeutics, and being unlikely to cause resistance. Provided is a pharmaceutical composition for cancer treatment prepared by a method having: a stem cell production step for making immortalized stem cells by introducing four types of genes into deciduous tooth dental pulp stem cells obtained from the dental pulp of mammals; and a condition medium preparation step for culturing the immortalized stem cells for a predetermined length of time in serum-free medium at 23-27° C. under conditions of low oxygen concentration at an oxygen concentration of from 0.5% to less than 20%, the pharmaceutical composition containing 1.5 times or more of insulin-like growth factor (IGF-1) and vascular endothelial growth factor (VEGF) than is contained in condition medium prepared when culturing at an oxygen concentration of 20% and otherwise identical conditions.


Find Patent Forward Citations

Loading…